Compare Northrop Grumman Corporation (NOC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs BIO-TECHNE Corp — how do they compare? Northrop Grumman Corporation trades at $524 (market cap $74.42B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Northrop Grumman Corporation is far larger — about 6.7× BIO-TECHNE Corp's market cap, and Northrop Grumman Corporation pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| NOC | TECH | |
|---|---|---|
Market Cap | $74.42B | $11.16B |
Sector | Industrials | Health |
52-Week High | $768.02 | $72.12 |
52-Week Low | $496.02 | $43.31 |
Enterprise Value | $88.65B | $11.24B |
Dividend Yield | 1.79% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
